HIV Infection Clinical Trial
Official title:
Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II
| Verified date | July 2016 |
| Source | University of North Carolina, Chapel Hill |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This is Phase II of a three stage project whose overall goals are to develop viable
community-based HIV prevention interventions and to form and maintain the necessary
community collaborations to support such Adolescent Trials Network (ATN) research
activities.
This phase will describe specific locations within high-risk areas where youth, ages 12-24,
spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at
these venues will be assessed by administering anonymous computerized interviews to eligible
and willing youth. This information will be shared with community partners during scheduled
working group meetings.
| Status | Completed |
| Enrollment | 16706 |
| Est. completion date | October 2010 |
| Est. primary completion date | October 2010 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 12 Years to 24 Years |
| Eligibility |
Inclusion Criteria: Index Subjects: - Documented HIV-infection - Acquisition of HIV after age 9 years - Verbal confirmation of 12-24 years of age - Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months - Ability to understand and willingness to provide informed consent/assent BVI subjects: - Youths who appear to be 12-24 years old HIV Serosurvey subjects at the venues: - Verbal confirmation of 12-24 years of age - Verbal report of having engaged in sexual activity (vaginal, anal and/or oral sex) within the past 12 months - Ability to understand and willingness to provide informed consent/assent Exclusion Criteria: - Visibly distraught and/or emotionally unstable (i.e. depressive mood, exhibiting manic, suicidal or violent behavior, etc.) - Visibly intoxicated or under the influence of psychoactive agents - Clinically presents as acutely ill |
| Country | Name | City | State |
|---|---|---|---|
| Puerto Rico | University Pediatric Hospital | San Juan | |
| United States | University of Maryland | Baltimore | Maryland |
| United States | Childrens' Hospital of Boston | Boston | Massachusetts |
| United States | Montefiore Medical Center, Adolescent AIDS Program | Bronx | New York |
| United States | Stroger Hospital of Cook County | Chicago | Illinois |
| United States | Children's Diag. and Treatment Center | Ft. Lauderdale | Florida |
| United States | Childrens Hospital of Los Angeles | Los Angeles | California |
| United States | University of Miami | Miami | Florida |
| United States | Tulane Medical Center | New Orleans | Louisiana |
| United States | Mount Sinai Medical Center | New York | New York |
| United States | Children's Hopsital of Philadelphia | Philadelphia | Pennsylvania |
| United States | UCSD Mother, Child & Adolescent HIV Program | San Diego | California |
| United States | Univ of Califormia at San Francisco | San Francisco | California |
| United States | USF Peds Div. of Infectious Disease | Tampa | Florida |
| United States | Children's Hospital National Medical Center | Washington | District of Columbia |
| Lead Sponsor | Collaborator |
|---|---|
| University of North Carolina, Chapel Hill | National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA) |
United States, Puerto Rico,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ascertain specific community venues where at-risk youth can be recruited for interventions within the high-risk areas identified in the first Phase of the study | The outcome measure will be assessed using results from: (a) Phase I mapping; (b) Phase II interviews with HIV-infected youth; and (c) Phase II Brief Venue Interviews (BVIs). Input from community partners and ethnographic procedures will add critical information. | One time assessment at 10 months | |
| Primary | Describe HIV risk behaviors of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months | |
| Primary | Describe social networks of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months | |
| Primary | Describe HIV seroprevalence of adolescents and young adults recruited from targeted venues | The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown. | One time assessment at 10 months | |
| Primary | Assess the characteristics of the community-researcher partnerships | The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. | One time assessment at 10 months | |
| Primary | Assess quality of the community-researcher partnerships | The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. | One time assessment at 10 months | |
| Primary | Assess outcomes of the community-researcher partnerships | The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept. | One time assessment at 10 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
| Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
| Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
| Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
| Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
| Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
| Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
| Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
| Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
| Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
| Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
| Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
| Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
| Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
| Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |